Biocryst Pharma Inc BCRX

$8.17 +0.05 (0.62%)

Valuation

Market cap
2,087,721,000
Revenue TTM
$874,840,000
Net income TTM
$263,860,000
PE ratio
5.60
Forward PE
—
Profit margin
30.16%
Debt to equity
-1.85

Trading

Volume
6,148,600
Avg volume
4,247,252
Day's range
$7.92 – $8.20
Shares out
255,535,000
Stochastic %K
22%
Beta
0.55
Analysts
Strong Sell
Price target
$20.45

Price

Company profile

BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is als...

Show more

BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Phone
919 859 1302
Website
https://www.biocryst.com
Address
4505 Emperor Boulevard, Suite 200, Durham, United States

Latest news

Stocktwits

Paulzk Oct 4, 3:23 AM
$BCRX way:"Entry level workers continue to face a difficult job market with limited opportunities even for the workers who have been able to find a job."
0 replies
Paulzk Oct 4, 3:22 AM
$BCRX But that post-Covid "Great Resignation" has given way to what is now being called the "Big Stay." At a time when hiring is slow and employers seem to have the upper hand, workers are far less likely to job hop and those who do switch jobs are seeing more meager pay gains. Just 1.9% of nonfarm workers quit their jobs this past August, down from 3% in April of 2022, the Bureau of Labor Statistics reports. "It's a solid labor market, but it's different for young people." How different? In the second quarter of 2026, the unemployment rate for all young workers, aged 22 to 27 was 7.2%, https://finance.yahoo.com/economy/articles/job-hopping-paid-off-older-103000150.html
0 replies
Paulzk Oct 4, 3:10 AM
$BCRX There is a deeper lesson here about our fiscal condition. Congress has irresponsibly rejected every mechanism of self-restraint. It had many chances to adopt budget rules, enact spending caps, make unpopular but necessary revenue enhancements, and reform entitlements. Each time parochial interests triumphed over statesmanship. Bondholders are the only remaining check on federal borrowing. And they are unforgiving.
0 replies
Paulzk Oct 3, 10:47 PM
$BCRX One possible explanation is that investors are losing faith in the dollar. Congress knows it can't touch the middle class and has no ideas about how to help them other than growing the debt–and it's headed for a bad outcome thanks to bond vigilantes https://finance.yahoo.com/economy/policy/articles/bond-market-reveals-congress-national-094500766.html
0 replies
Paulzk Oct 3, 10:42 PM
$BCRX But it's no coincidence that long-duration Treasury bond yields have ascended to the heavens this year. The 30-year Treasury bond yield has topped 5.5%, a level last seen in 2003, while the 10-year yield -- the benchmark for mortgage rates -- has soared to 5.25%, a 19-year high. 1. Trumpflation 2. Runaway national debt 3. AI hyperscalers are competing for capital https://finance.yahoo.com/economy/policy/articles/president-donald-trump-claims-interest-082602813.html
0 replies
Paulzk Oct 3, 10:17 PM
$BCRX No country ever printed it's way to greatness.
0 replies
Paulzk Oct 3, 10:14 PM
$BCRX This is the most shameful thing I have seen a president do. Giving everyone a $5,000 check is just a sugar high. It will just lead to higher inflation long term. After a short time the poor and middle class will be poorer. Rates will be higher and it will be harder to sell US bonds. This is just an invitation to misery by a very corrupt man. "Only I can make you this promise: If Republicans win the House of Representatives and the Senate in the 2026 Midterm Elections, I'm going to give all Adult Citizens in the United States of America, $5,000. " https://finance.yahoo.com/economy/article/only-i-can-make-you-this-promise-trump-re-ups-pledge-to-send-americans-5000-if-gop-wins-135647789.html
1 replies
milt0n Oct 3, 12:43 PM
$BCRX Another senior position posting from yesterday: VP, Drug Substance, and some key takeaways from the job description. https://www.linkedin.com/jobs/view/vp-drug-substance-at-biocryst-pharmaceuticals-inc-4472857108 The VP will own drug-substance strategy across “small-molecule active pharmaceutical ingredients and biologic drug substances, from candidate selection and early development through late-stage development, validation, launch readiness, commercialization, and lifecycle management.”. Also explicitly says the role owns drug-substance strategy across the portfolio and participates in: “portfolio reviews, due diligence … and technology or innovation evaluations.” “Due diligence” is the key phrase . From the hiring I have tracked for the past several months, this seems to support the end-to-end drug-development organization they are trying to achieve minus internal discovery. Buy/license promising science rather than inventing everything yourself, then use the company’s internal expertise to develop and commercialize it.
2 replies